Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.8899
-0.0101 (-1.12%)
At close: May 8, 2026, 4:00 PM EDT
0.8801
-0.0098 (-1.10%)
After-hours: May 8, 2026, 7:48 PM EDT

Company Description

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.

The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.

It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Oncolytics Biotech Inc.
Oncolytics Biotech logo
CountryUnited States
Founded1998
IPO DateNov 8, 1999
IndustryBiotechnology
SectorHealthcare
Employees29
CEOJared Kelly

Contact Details

Address:
4350 Executive Drive, Suite 325
San Diego, California 92121
United States
Phone403 670 7377
Websiteoncolyticsbiotech.com

Stock Details

Ticker SymbolONCY
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001129928
CUSIP Number68237V103
ISIN NumberUS68237V1035
Employer ID98-0541667
SIC Code2834

Key Executives

NamePosition
Jared Kelly J.D., L.L.M.Chief Executive Officer and Director
Kirk J. Look C.A., CPAChief Financial Officer
Dr. Thomas C. Heineman M.D., Ph.D.Chief Medical Officer
John McAdoryExecutive Vice President of Strategy and Operations
Allison Hagerman P.Eng., P.M.P.Chief Technology Officer
Jon PattonDirector of Investor Relations and Communication
Andrew P. AromandoChief Business Officer
Yujun WuVice President and Head of Biostatistics
John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A.Consultant

Latest SEC Filings

DateTypeTitle
May 4, 20268-KCurrent Report
Apr 27, 20268-KCurrent Report
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling
Apr 8, 2026F-10POSFiling